10.1177_1758834018757175-fig1.jpg

Treatment of uveal melanoma: where are we now?

In this paper, the authors discuss the various treatments evaluated in the setting of metastatic uveal melanoma. Trough the understanding of uveal melanoma’s biology, immunotherapy efficacy may be improved after priming the tumour from immunologically “cold” to “hot” with a new molecule.

Abstract

Uveal melanoma, a rare subset of melanoma, is the most common primary intraocular malignancy in adults. Despite effective primary therapy, nearly 50% of patients will develop metastatic disease. Outcomes for those with metastatic disease remain dismal due to a lack of effective therapies. The unique biology and immunology of uveal melanoma necessitates the development of dedicated management and treatment approaches. Ongoing efforts seek to optimize the efficacy of targeted therapy and immunotherapy in both the adjuvant and metastatic setting. This review provides a comprehensive, updated overview of disease biology and risk stratification, the management of primary disease, options for adjuvant therapy, and the current status of treatment strategies for metastatic disease.

A digest of this paper is available here.

To download this paper, please click here.